GENEDRIVE PLC (GDR) — Interim results presentation

Investor webinar replay

Replay transcript excerpt

Good morning, ladies and gentlemen, and welcome to the GENEDRIVE PLC Interim Results Investor Presentation. Throughout this recorded presentation, investors will be in listen only mode. Questions are encouraged and can be submitted at any time using the Q and A tab situated on the right hand corner of your screen. Just please simply type in your question at any time and press send. The company may not be in a position to answer every question received during the meeting itself. However, the company will review all questions submitted today and publish responses where it's appropriate to do so. Before we begin, we'd like to submit the following poll. And if you give that your kind attention, I'm sure the company will be most grateful. And I'd now like to hand over to Matthew Fowler, CFO, and David Budd, CEO from GENEDRIVE. Good morning to you both. Morning, Mark. Thanks for the, introduction, and good morning to everyone. My name is Dave Budd. I'm the chief executive here at GENEDRIVE. And as Mark mentioned, Matthew Fowler, our our chief financial officer is joining. And we're here to present, our highlights from our interim results to December 2021 and update you on the progress of the company since that point of time. Usual, document disclaimer there that you can read. For those of you potentially new to the GENEDRIVE story, just a little bit of background. The GENEDRIVE device itself is a small portable genetic reader, which is used to derive genetic information about people or or pathogens or environments. And then we use that genetic information often to give us, you know, the the option to make different medical decisions based on on someone's genetic status. Some of these products themselves and the important pieces needed to launch them were just coming into p...